Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Inclusion Criteria:

Histologically confirmed Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) (small lymphocytic lymphoma may be included)
Relapsed or refractory after at least one regimen and with no curative option with conventional therapy
Bidimensionally measurable disease (at least 2 cm)
No evidence of cerebral or meningeal involvement by lymphoma
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Signed informed consent form prior to enrollment
Women of childbearing potential and men must use two forms of contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a women become pregnant or suspect she is pregnant while she or her partner is participating in this study, the patient should inform the treating physician immediately

Exclusion Criteria:

Burkitt's lymphoma, lymphoblastic lymphoma, chronic lymphocytic leukemia and cutaneous T-cell lymphoma
Chemotherapy or radiation therapy or other investigational agents within 3 weeks prior to entering the study unless there is clear evidence of progression of disease and toxicity from previous treatment has resolved in which case study entry may be within 1 week of last treatment
Previous radioimmunotherapy within 12 weeks
Patients with known immunodeficiency virus (HIV) infection must not have cluster of differentiation (CD)4 cells < 400/mm^3 and who must not have a prior acquired immunodeficiency syndrome (AIDS)-defining diagnosis and cannot be on antiretroviral therapy for HIV
Known active viral hepatitis
Any serious active disease or co-morbid condition, which in the opinion of the principal investigator, will interfere with the safety or with compliance with the study
Absolute neutrophil count < 1.5 x 10^9/L
Platelets < 75 x 10^9/L
Total bilirubin > 1.5 x upper limit of normal (ULN) (> 3 x ULN for patients with liver involvement)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 2.5 x ULN (> 5 x ULN for patients with liver involvement)
Serum creatinine > 2 x ULN
Hemoglobin (Hb)A1C > 8%
Patients receiving any medications or substances that are inhibitors of cytochrome P450 family 3, subfamily A, polypeptide 4 (CYP 450 3A4) are ineligible
Patients with diabetes or in risk for hyperglycemia should not be excluded from trials with MK-2206, but the hyperglycemia should be well controlled on oral agents before the patient enters the trial
Cardiovascular: baseline Fredericia corrected QT interval (QTcF) > 450 msec (male) or QTcF > 470 msec (female) will exclude patients from entry on study
Significant heart block or baseline bradycardia < 50 beats per minute (bpm) due to cardiac disease
Patients who are pregnant or breastfeeding